Study to assess the safety and tolerability of ascending single-doses of REGN1193 in healthy volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
56
Unnamed facility
Dallas, Texas, United States
Number of TEAEs
The primary endpoint in this study is the incidence and severity of TEAEs (treatment emergent adverse events) in healthy volunteers treated with REGN1193 or placebo reported from day 1 (baseline) to the completion of the study on day 106/ visit 16.
Time frame: day 1 to day 106
Serum concentration
Serum concentrations of REGN1193 over time
Time frame: day 1 to day 106
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.